Skip to content

Our Pipeline

We are building a strong and diversified proprietary pipeline of innovative, single-pill, fixed dose combination therapies in late-stage development, targeting some of the biggest killers in both developed and developing countries, include cardiovascular disease, hypertension, and type 2 diabetes. Our most advanced candidate, GMRx2, is a single pill triple combination in novel and proprietary dosage strengths, targeted for first line therapy to control hypertension.

No.4 Fact

Our business model avoids the early, high-risk stages of drug discovery and development, reducing time-to-market, bringing a higher probability of success and requiring less capital investment to bring our medicines to patients than is usual in the industry

The Overview

At George Medicines, we are focused on developing late-stage drugs to improve upon existing treatments of non-communicable diseases through innovative, sustainable, and more patient-friendly methods.

We are developing an innovative pipeline of candidates targeting some of the world’s leading causes of death annually including hypertension, atherosclerotic diseases and diabetes.

By combining established drugs in innovative fixed-dose formulations, George Medicines is creating treatments that are more efficacious, safer, and affordable than the current alternatives.

We understand the financial burden associated with current medications and the resultant impact on accessibility to regions worldwide. With all our products in development, accessibility is a core focus regardless of the region.

The George Medicines Pipeline

GMRx2
Phase 3
Anticipated Market Launch
2023

GMRx2 is a three-drug ultra-low-dose combination containing telmisartan, amlodipine and indapamide, designed for the treatment of hypertension, including initial treatment. Through this innovative combination, in fixed dose formulation, we aim to tackle the growing issue of hypertension, one of the leading causes to cardiovascular disease and morbidity while improving accessibility in key markets across the globe1,2. GMRx2 offers an optimal balance of reducing side effects associated with current treatments, while increasing both efficacy and patient adherence to the therapy, potentially aiding millions globally.

In the US alone, only a third of those treated for hypertension achieve the adequate level of blood pressure with current treatments at their prescribed doses, while many receive more than one drug3.

Through the ultra-low dose formulation, GMRx2 aims to:

  • Reduce blood pressure to adequate blood pressure levels4
  • Reduce the likelihood of side effects compared to currently prescribed doses5
  • Increase adherence due the reduction in number of pills

GMRx1
Phase 3 Ready
Anticipated Market Launch
2023/24

GMRx1 is a four drug fixed combination approach for the prophylactic treatment of atherosclerotic diseases, one of the main underlying causes of cardiovascular disease (CVD). Atherosclerotic diseases are slow, with a lifelong progression of changes in the blood vessels, of which the causes remain unknown, however, high blood pressure, elevated levels of cholesterol and triglycerides, diabetes and smoking elevate the risk of developing atherosclerotic diseases.


GMRx3 & GMRx4
In Development
Anticipated Market Launch
2025

GMRx3 and GMRx4 consists of two sets of three ultra-low-dose blood glucose lowering medicines to treat those with type 2 diabetes, which accounts for around 90% of those diagnosed with diabetes mellitus. Worldwide, approximately 460 million adults are living with diabetes, which is expected to grow to 700 million by 2045. Type 2 diabetes is characterised by insulin resistance where the body does not fully respond to insulin, resulting in the rise of blood glucose and further rise in insulin release. This process can exhaust the pancreas resulting in reduced insulin production causing higher blood sugar levels. With GMRx3 and GMRx4, we aim to reduce blood glucose levels while reducing the number of medicines required with current treatments.


References

1Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990?2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012;380(9859):2224-60.
2Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-35.
3Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959-68.
4Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015–2016.
5Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018:ehy339-ehy.